Payment overview · 2025
General Payments
$376.52
20 reported records · 10 companies
Healthcare provider profile · identity verified
David Glenn Nelson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1396752259
Verified facts
What the public records show
CMS Open Payments records show David Glenn Nelson, M.D. received $376.52 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.97 | 20.7% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $71.91 | 19.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.73 | 15.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.90 | 15.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.77 | 5.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.42 | 5.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.83 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.47 | 4.6% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $16.70 | 4.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.82 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.52 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $71.91 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.73 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.90 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 101 |
| Losartan Potassium | Losartan Potassium | 254 | 91 |
| Lisinopril | Lisinopril | 232 | 77 |
| Montelukast Sodium | Montelukast Sodium | 199 | 71 |
| Gabapentin | Gabapentin | 195 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 54 |
| Ozempic | Semaglutide | 149 | 29 |
| Trazodone Hcl | Trazodone Hcl | 148 | 47 |
| Meloxicam | Meloxicam | 147 | 51 |
| Metformin Hcl Er | Metformin Hcl | 146 | 45 |
| Methylprednisolone | Methylprednisolone | 145 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 47 |
| Metformin Hcl | Metformin Hcl | 139 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 132 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 43 |
| Omeprazole | Omeprazole | 128 | 45 |
| Azithromycin | Azithromycin | 122 | 98 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 29 |
| Furosemide | Furosemide | 114 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 23 |
| Simvastatin | Simvastatin | 97 | 30 |
| Cefdinir | Cefdinir | 85 | 75 |
| Prednisone | Prednisone | 84 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 25 |
| Mupirocin | Mupirocin | 78 | 36 |
| Celecoxib | Celecoxib | 72 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 19 |
| Atenolol | Atenolol | 61 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 20 |
| Estradiol | Estradiol | 58 | 15 |
| Glimepiride | Glimepiride | 57 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 20 |
| Alprazolam | Alprazolam | 55 | 21 |
| Buspirone Hcl | Buspirone Hcl | 55 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Famotidine | Famotidine | 53 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 39 |
| Carvedilol | Carvedilol | 51 | 20 |
| Ondansetron Odt | Ondansetron | 51 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 28 |
| Sertraline Hcl | Sertraline Hcl | 48 | 17 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 16 |
| Mirtazapine | Mirtazapine | 41 | 15 |
| Valsartan | Valsartan | 41 | 12 |
| Allopurinol | Allopurinol | 40 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 25 |
| Methocarbamol | Methocarbamol | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Pregabalin | Pregabalin | 38 | 20 |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 15 |
| Tramadol Hcl | Tramadol Hcl | 35 | 16 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 16 |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 12 |
| Baclofen | Baclofen | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 13 |
| Potassium Chloride | Potassium Chloride | 30 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 14 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 18 |
| Azelastine Hcl | Azelastine Hcl | 28 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 14 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 12 |
| Farxiga | Dapagliflozin Propanediol | 26 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Ofloxacin | Ofloxacin | 26 | 24 |
| Terbinafine Hcl | Terbinafine Hcl | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Ciclopirox | Ciclopirox Olamine | 23 | 15 |
| Eliquis | Apixaban | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Tadalafil | Tadalafil | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Glipizide | Glipizide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.52 · 20 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, INSPIRE, Kerendia, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, ZILVER PTX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error